Trial Profile
A real world study of bone targeted agents among patients with metastatic solid tumors.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid (Primary)
- Indications Bone metastases; Breast cancer; Lung cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- 20 Nov 2017 New trial record